How Bullish Analyst Coverage and New Capital Raise Could Impact Olema Pharmaceuticals (OLMA) Investors [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
the company advances Phase 3 and Phase 1 oncology trials supported by fresh capital from a November 2025 public offering of about US$218.50 million. This cluster of optimistic research views and Olema's strengthened funding position underscores growing market focus on potential near-term clinical and regulatory milestones in its breast cancer pipeline. Next, we'll examine how the upbeat analyst coverage and upcoming 90-day catalyst watch could shape Olema Pharmaceuticals' investment narrative. The latest GPUs need a type of rare earth metal called Neodymium and there are only 39 companies in the world exploring or producing it . Find the list for free. For Olema to make sense in a portfolio, an investor has to believe that its lead breast cancer candidate, palazestrant, and earlier-stage OP-3136 can eventually justify a business that today has no revenue and is running sizeable losses. The recent wave of upbeat analyst coverage, capped by UBS initiating with a positive stance
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Olema Insider Sells $8 Million in Shares After 300% Stock Surge [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals (NASDAQ:OLMA) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- The banker, the brothers, the friends and their frauds [Investment Executive - News]Investment Executive - News
- Olema Pharmaceuticals (NASDAQ:OLMA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.MarketBeat
- Olema Pharmaceuticals (NASDAQ:OLMA) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.MarketBeat
OLMA
Earnings
- 11/10/25 - Miss
OLMA
Sec Filings
- 1/12/26 - Form 8-K
- 1/12/26 - Form 144
- 12/30/25 - Form 4
- OLMA's page on the SEC website